Korean J Gastroenterol.  2024 Aug;84(2):98-101. 10.4166/kjg.2024.075.

What is Duodenal Mucosal Resurfacing?

• Cha B

• KMID: 2558896
• DOI: http://doi.org/10.4166/kjg.2024.075

Figure

• 

  Fig. 1 Duodenal mucosal surfacing (DMR) catheter system.

Reference

1. van Baar ACG, Devière J, Hopkins D, et al. 2022; Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study). Diabetes Res Clin Pract. 184:109194. DOI: 10.1016/j.diabres.2022.109194. PMID: 35032562.

2. Mingrone G, van Baar AC, Devière J, et al. 2022; Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut. 71:254–264. DOI: 10.1136/gutjnl-2020-323608. PMID: 33597157. PMCID: PMC8761999.

3. Busch CBE, Meiring S, van Baar ACG, et al. Insulin sensitivity and beta cell function after Duodenal Mucosal Resurfacing (DMR): An Open-Label, Mechanistic, Pilot Study. Gastrointest Endosc. 2024; Jan. 25. doi: 10.1016/j.gie.2024.01.031. DOI: 10.1016/j.gie.2024.01.031. PMID: 38280531.

4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38:140–149. DOI: 10.2337/dc14-2441. PMID: 25538310.

5. Egede LE, Gebregziabher M, Dismuke CE, et al. 2012; Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care. 35:2533–2539. DOI: 10.2337/dc12-0572. PMID: 22912429. PMCID: PMC3507586.

6. Zervos EE, Agle SC, Warren AJ, et al. 2010; Amelioration of insulin requirement in patients undergoing duodenal bypass for reasons other than obesity implicates foregut factors in the pathophysiology of type II diabetes. J Am Coll Surg. 210:564–572. 572–574. DOI: 10.1016/j.jamcollsurg.2009.12.025. PMID: 20421005.

7. Laferrère B, Reilly D, Arias S, et al. 2011; Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med. 3:80re2. DOI: 10.1126/scitranslmed.3002043. PMID: 21525399. PMCID: PMC3656497.

8. Salinari S, le Roux CW, Bertuzzi A, Rubino F, Mingrone G. 2014; Duodenal-jejunal bypass and jejunectomy improve insulin sensitivity in Goto-Kakizaki diabetic rats without changes in incretins or insulin secretion. Diabetes. 63:1069–1078. DOI: 10.2337/db13-0856. PMID: 24241532.

9. Jacobsen SH, Olesen SC, Dirksen C, et al. 2012; Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg. 22:1084–1096. DOI: 10.1007/s11695-012-0621-4. PMID: 22359255.

10. Rubino F, Marescaux J. 2004; Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 239:1–11. DOI: 10.1097/01.sla.0000102989.54824.fc. PMID: 14685093. PMCID: PMC1356185.

11. Rubino F, Forgione A, Cummings DE, et al. 2006; The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 244:741–749. DOI: 10.1097/01.sla.0000224726.61448.1b. PMID: 17060767. PMCID: PMC1856597.

12. Gniuli D, Calcagno A, Dalla Libera L, et al. 2010; High-fat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide (GIP)-expressing cell hyperplasia in the duodenum of Wistar rats. Diabetologia. 53:2233–2240. DOI: 10.1007/s00125-010-1830-9. PMID: 20585935.

13. Ferrannini E, Mingrone G. 2009; Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care. 32:514–520. DOI: 10.2337/dc08-1762. PMID: 19246589. PMCID: PMC2646039.

14. Dirksen C, Hansen DL, Madsbad S, et al. 2010; Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report. Diabetes Care. 33:375–377. DOI: 10.2337/dc09-1374. PMID: 19918005. PMCID: PMC2809286.

15. Shimizu H, Eldar S, Heneghan HM, Schauer PR, Kirwan JP, Brethauer SA. 2014; The effect of selective gut stimulation on glucose metabolism after gastric bypass in the Zucker diabetic fatty rat model. Surg Obes Relat Dis. 10:29–35. DOI: 10.1016/j.soard.2013.01.021. PMID: 23507630.

16. Haidry RJ, van Baar AC, Galvao Neto MP, et al. 2019; Duodenal mucosal resurfacing: proof-of-concept, procedural development, and initial implementation in the clinical setting. Gastrointest Endosc. 90:673–681.e2. DOI: 10.1016/j.gie.2019.03.024. PMID: 30935932.

17. Rajagopalan H, Cherrington AD, Thompson CC, et al. 2016; Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care. 39:2254–2261. DOI: 10.2337/dc16-0383. PMID: 27519448.

18. van Baar ACG, Holleman F, Crenier L, et al. 2020; Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. Gut. 69:295–303. DOI: 10.1136/gutjnl-2019-318349. PMID: 31331994. PMCID: PMC6984054.